The primary actors involved in the response to the Marburg virus disease (MVD) outbreak in Rwanda include the Rwanda Ministry of Health and the Rwanda Biomedical Centre (RBC), which have led the national response. International support has been provided by the World Health Organization (WHO), the Africa CDC, and UNICEF. Clinical and research contributions have been facilitated by institutions such as Oxford University and the Africa Health Sciences University.

Rwanda is managing an outbreak of the Marburg virus, a highly infectious and often fatal filovirus related to Ebola. The outbreak, which began in late 2024, has seen 66 confirmed cases and 15 deaths. The current phase involves a 42-day monitoring period to ensure no new cases emerge, a standard protocol for declaring an outbreak over. The response has focused on contact tracing, early detection, and the deployment of viral load testing hubs.

The outbreak is centered in Rwanda, with significant clinical activity in Kigali. The virus is known to circulate in East and Central Africa, with recent research suggesting that the pathogen may persist in animal reservoirs, such as those found in caves in neighboring Uganda.

The first outbreak was declared on September 27, 2024. Following a period of intensive response, the government declared the initial outbreak over on December 20, 2024. However, ongoing surveillance and monitoring continue through late 2026, with the most recent data updates provided in November 2026.

The primary motivation for the response is to prevent the spread of a high-mortality pathogen that poses a significant threat to regional and global health security. The One Health approach, supported by the Pandemic Fund, aims to integrate human, animal, and environmental health data to improve surveillance and response times.

The response utilizes a combination of epidemiologic surveillance, laboratory testing, and community engagement. The Field Epidemiology Training Program (FETP) has been instrumental in training local disease detectives who lead the response. Financial support has been bolstered by grants from the Pandemic Fund and co-investments from international partners, allowing for the rapid scaling of diagnostic and clinical capabilities.

The primary actors involved in this response include the World Health Organization (WHO), which is coordinating the international response and vaccine trials, and the Democratic Republic of the Congo (DRC), the epicenter of the outbreak. Other key stakeholders include the Africa Centres for Disease Control and Prevention (Africa CDC), which is working alongside the WHO, and various international health experts deployed by the EU Health Task Force (EUHTF) to support preparedness in the DRC, Kenya, Uganda, and South Sudan. Pharmaceutical developers and research institutions are also critical, as they provide the candidate vaccines currently entering clinical trials.

The current development is the official approval of clinical trials for two new candidate vaccines to combat the Bundibugyo Ebola virus. This strain has caused a significant outbreak in the DRC, with over 10,600 confirmed cases and 5,198 deaths reported as of early November 2026. The outbreak has been declared a Public Health Emergency of International Concern (PHEIC) by the WHO. The new vaccine trials are intended to supplement existing response measures, which include contact tracing, isolation, and community engagement, as the virus has shown signs of spreading beyond the DRC into neighboring countries.

The outbreak is primarily concentrated in the Democratic Republic of the Congo, specifically affecting eight provinces including Ituri. The virus has also been detected in Kenya, Nigeria, and France, with France reporting a case involving a doctor who returned from a humanitarian mission. The geographic spread has necessitated a multi-country response, with international experts deployed to several African nations to bolster surveillance and containment efforts.

The outbreak has been ongoing since May 2026, when the WHO first declared it a PHEIC. As of November 4, 2026, the WHO has officially approved the new vaccine trials. The response has been continuous, with various milestones including the end of the outbreak in Uganda in August 2026 and ongoing monitoring by the ECDC and WHO. The situation remains fluid, with daily updates provided by the DRC government and international health bodies.

The primary motivation for the vaccine trials is the high mortality rate associated with the Bundibugyo strain and the failure of current containment strategies to fully halt the spread of the virus. The WHO and its partners are seeking to reduce the burden of the disease, which has overwhelmed local healthcare systems and caused significant social and economic disruption. The expansion of the outbreak to multiple countries has increased the urgency for effective medical countermeasures.

The response is managed through a combination of epidemiological surveillance, clinical research, and international coordination. The WHO utilizes the International Health Regulations (IHR) framework to monitor the outbreak and coordinate the response. Vaccine trials are conducted through established clinical research protocols, ensuring that safety and efficacy data are collected systematically. The deployment of experts by the EUHTF and other international bodies provides technical support to local health authorities, facilitating the implementation of standardized response measures across affected regions.

The primary actors involved in the response to the Marburg virus disease (MVD) outbreak in Rwanda include the Rwanda Ministry of Health and the Rwanda Biomedical Centre (RBC), which have led the national response. International support has been provided by the World Health Organization (WHO), the Africa CDC, and UNICEF. Clinical and research contributions have been facilitated by institutions such as Oxford University and the Africa Health Sciences University.

Rwanda is managing an outbreak of the Marburg virus, a highly infectious and often fatal filovirus related to Ebola. The outbreak, which began in late 2024, has seen 66 confirmed cases and 15 deaths. The current phase involves a 42-day monitoring period to ensure no new cases emerge, a standard protocol for declaring an outbreak over. The response has focused on contact tracing, early detection, and the deployment of viral load testing hubs.

The outbreak is centered in Rwanda, with significant clinical activity in Kigali. The virus is known to circulate in East and Central Africa, with recent research suggesting that the pathogen may persist in animal reservoirs, such as those found in caves in neighboring Uganda.

The first outbreak was declared on September 27, 2024. Following a period of intensive response, the government declared the initial outbreak over on December 20, 2024. However, ongoing surveillance and monitoring continue through late 2026, with the most recent data updates provided in November 2026.

The primary motivation for the response is to prevent the spread of a high-mortality pathogen that poses a significant threat to regional and global health security. The One Health approach, supported by the Pandemic Fund, aims to integrate human, animal, and environmental health data to improve surveillance and response times.

The response utilizes a combination of epidemiologic surveillance, laboratory testing, and community engagement. The Field Epidemiology Training Program (FETP) has been instrumental in training local disease detectives who lead the response. Financial support has been bolstered by grants from the Pandemic Fund and co-investments from international partners, allowing for the rapid scaling of diagnostic and clinical capabilities.

The primary actors involved in this response include the World Health Organization (WHO), which is coordinating the international response and vaccine trials, and the Democratic Republic of the Congo (DRC), the epicenter of the outbreak. Other key stakeholders include the Africa Centres for Disease Control and Prevention (Africa CDC), which is working alongside the WHO, and various international health experts deployed by the EU Health Task Force (EUHTF) to support preparedness in the DRC, Kenya, Uganda, and South Sudan. Pharmaceutical developers and research institutions are also critical, as they provide the candidate vaccines currently entering clinical trials.

The current development is the official approval of clinical trials for two new candidate vaccines to combat the Bundibugyo Ebola virus. This strain has caused a significant outbreak in the DRC, with over 10,600 confirmed cases and 5,198 deaths reported as of early November 2026. The outbreak has been declared a Public Health Emergency of International Concern (PHEIC) by the WHO. The new vaccine trials are intended to supplement existing response measures, which include contact tracing, isolation, and community engagement, as the virus has shown signs of spreading beyond the DRC into neighboring countries.

The outbreak is primarily concentrated in the Democratic Republic of the Congo, specifically affecting eight provinces including Ituri. The virus has also been detected in Kenya, Nigeria, and France, with France reporting a case involving a doctor who returned from a humanitarian mission. The geographic spread has necessitated a multi-country response, with international experts deployed to several African nations to bolster surveillance and containment efforts.

The outbreak has been ongoing since May 2026, when the WHO first declared it a PHEIC. As of November 4, 2026, the WHO has officially approved the new vaccine trials. The response has been continuous, with various milestones including the end of the outbreak in Uganda in August 2026 and ongoing monitoring by the ECDC and WHO. The situation remains fluid, with daily updates provided by the DRC government and international health bodies.

The primary motivation for the vaccine trials is the high mortality rate associated with the Bundibugyo strain and the failure of current containment strategies to fully halt the spread of the virus. The WHO and its partners are seeking to reduce the burden of the disease, which has overwhelmed local healthcare systems and caused significant social and economic disruption. The expansion of the outbreak to multiple countries has increased the urgency for effective medical countermeasures.

The response is managed through a combination of epidemiological surveillance, clinical research, and international coordination. The WHO utilizes the International Health Regulations (IHR) framework to monitor the outbreak and coordinate the response. Vaccine trials are conducted through established clinical research protocols, ensuring that safety and efficacy data are collected systematically. The deployment of experts by the EUHTF and other international bodies provides technical support to local health authorities, facilitating the implementation of standardized response measures across affected regions.